
Opinion|Videos|February 20, 2024
Case 2: 82-Year-Old Former Smoker with Poorly Differentiated Lung Adenocarcinoma and PD-L1 of 85%
Dr. Gregory Gan introduces Case 2, featuring an 82-year-old former smoker with poorly differentiated lung adenocarcinoma and a PD-L1 level of 85%, initiating a conversation on the role of a multidisciplinary approach to treatment and consideration factors for surgical and radiotherapy interventions.
Advertisement
Episodes in this series

Advertisement
Related to this article

In pooled phase 1/2 data, the PD-1/VEGF bispecific antibody cesalatamig produced a 33% objective response rate in PD-(L)1–resistant/refractory NSCLC.

Chinmay Jani, MD, describes how he counsels patients with and without a smoking history on a lung cancer diagnosis.

Chinmay Jani, MD, discusses ASCO 2026 data on lung cancer trends in younger adults and why this group has been overlooked.

Chinmay Jani, MD, explains how air pollution and asbestos contribute to lung cancer deaths beyond tobacco.

Findings may provide reassurance to patients with early-stage disease that surgery may help improve survival rates.

Chinmay Jani, MD, highlights nonsmoking risk factors, the impact of lung cancer on younger populations, and the value of comprehensive molecular testing.

Dwight H. Owen, MBBCh, MS, discussed why severe immune-related toxicities remain hard to predict as immunotherapy combinations expand in lung cancer.
Advertisement
Advertisement
Trending on CancerNetwork
1
Azacitidine Plus Ruxolitinib Shows Durable Responses in Myelofibrosis
2
Defining the Optimal Window for Cytoreductive SABR in Metastatic Kidney Cancer
3
Building Systems to Catch Liver and Other Cancers in Patients With MASLD
4
Rusfertide Improves Hematocrit Control vs Placebo in Polycythemia Vera
5


